The CANHEART ‘big data’ research initiative is aimed at measuring and improving cardiovascular health and the quality of ambulatory cardiovascular care provided in Ontario, Canada using the population-based CANHEART cohorts. The CANHEART cohorts were created through the linkage of 19+ routinely collected health administrative, vital statistics, survey and laboratory databases housed at ICES. The strength of these cohorts lies in the large sample size, containing information on 9.8 million Ontarians age 20-105 years, and diversity of the linked databases.
Building upon the insights gained to date through the CANHEART work, we have recently launched a new CANHEART SPOR project aimed at leveraging big data to conduct innovative cardiovascular clinical trials. We aim to: 1) undertake a pragmatic cluster randomized registry-based clinical trial to improve lipid-management amongst intermediate-and high-risk patients residing in high-risk health regions in Ontario (called CHOICES), and 2) develop novel algorithms for measuring clinical outcomes in clinical trials using health-related databases and compare whether they are as accurate as traditional event ascertainment methods in a prospective clinical trial (called INVESTED). These projects will be undertaken by an interdisciplinary team consisting of experts in administrative health databases, implementation science, clinical trials, knowledge translation and patient engagement.
A. Jurek, S. Greenland, G. Maldonado, and T. Church. International journal of epidemiology, 34 (3):
680-7(June 2005)3939<m:linebreak></m:linebreak>Mesures d'associació.
A. Barratt, P. Wyer, R. Hatala, T. McGinn, A. Dans, S. Keitz, V. Moyer, and G. For. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 171 (4):
353-8(August 2004)3595<m:linebreak></m:linebreak>A companion version of this article directed at teachers of evidence-based medicine http://www.cmaj.ca/cgi/data/171/4/353/DC1/1 - * An interactive version of this article as well as other tools and resources can be found at http://www.ebmtips.net/risk001.asp.;<m:linebreak></m:linebreak>Mesures d'associació.
D. Easton, J. Peto, and A. Babiker. Statistics in medicine, 10 (7):
1025-35(July 1991)4288<m:linebreak></m:linebreak>LR: 20061115; PUBM: Print; JID: 8215016; 0 (Contraceptives, Oral); CIN: Stat Med. 2004 Jan 15;23(1):93-104. PMID: 14695642; ppublish;<m:linebreak></m:linebreak>Mesures d'associació.
J. Llorca, and M. Delgado-Rodríguez. Gaceta sanitaria / S.E.S.P.A.S, 13 (5):
399-406(1999)2901<m:linebreak></m:linebreak>Anàlisi de supervivència; Competing risks.
C. West, and D. Dupras. Vaccine, 31 (12):
1550-2(March 2013)CI: Copyright (c) 2012; JID: 8406899; 2012/08/14 received; 2012/11/14 revised; 2012/11/28 accepted; 2012/12/11 aheadofprint; ppublish;<br/><br/>Critical appraisal; Interpretació de resultats; Errors; Risc relatiu vs absolut<br/><br/>Bona Figura de risc relatiu vs absolut.
A. Figueiras, F. Tato, B. Takkouche, and J. Gestal-Otero. European journal of clinical pharmacology, 51 (6):
445-8(January 1997)6054<m:linebreak></m:linebreak>LR: 20061115; JID: 1256165; ppublish;<m:linebreak></m:linebreak>Disseny; Tipus d'estudis.
S. Lagakos. The New England journal of medicine, 355 (2):
113-7(July 2006)4860<m:linebreak></m:linebreak>LR: 20071115; JID: 0255562; 0 (Cyclooxygenase 2 Inhibitors); 0 (Lactones); 0 (Sulfones); 0 (rofecoxib); CON: N Engl J Med. 2005 Mar 17;352(11):1092-102. PMID: 15713943; 2006/06/26 aheadofprint; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.
K. Wilson, and S. Hawken. Pharmacoepidemiology and drug safety, 22 (1):
108-10(January 2013)6932<br/>JID: 9208369; aheadofprint;<br/>Tipus d'estudis; Self controlled case series; Tamaño del efecto; Risc relatiu vs absolut.
G. Smith. Journal of epidemiology and community health, 60 (5):
382-8(May 2006)4828<m:linebreak></m:linebreak>JID: 7909766; 57-88-5 (Cholesterol); 9001-32-5 (Fibrinogen); ppublish;<m:linebreak></m:linebreak>Epidemiologia genètica.
M. Bobbio, B. Demichelis, and G. Giustetto. Lancet, 343 (8907):
1209-11(May 1994)6680<m:linebreak></m:linebreak>LR: 20071115; JID: 2985213R; OID: KIE: 43813; OTO: KIE; GN: KIE: KIE BoB Subject Heading: human experimentation/research design; GN: KIE: KIE BoB Subject Heading: patient care/drugs; GN: KIE: Full author name: Bobbio, Marco; GN: KIE: Full author name: Demichelis, Brunella; GN: KIE: Full author name: Giustetto, Guido; ppublish;<m:linebreak></m:linebreak>Presentació de dades.
K. Flegal, B. Graubard, and D. Williamson. American journal of epidemiology, 160 (4):
331-8(August 2004)4391<m:linebreak></m:linebreak>LR: 20041117; PUBM: Print; JID: 7910653; ppublish;<m:linebreak></m:linebreak>Risc atribuïble.